ProCE Banner Activity

Evolving Role for BCMA-Targeted Therapies for MM

Slideset Download
Download this slideset based on content from the annual CCO/IMF satellite symposium at ASH on BCMA-targeted treatment options for patients with relapsed/refractory multiple myeloma.

Released: December 15, 2021

Expiration: December 14, 2022

Share

Faculty

Thomas G. Martin

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Genentech, a member of the Roche Group

GlaxoSmithKline

Janssen administered by Scientific Affairs

Karyopharm Therapeutics

Oncopeptides

Pfizer, Inc.

Sanofi Genzyme

Partners

International Myeloma Foundation

ProCE Banner

Faculty Disclosure

Primary Author

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California